Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. CRNX
CRNX logo

CRNX News & Events

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

CRNX News

Ademi LLP Investigates Crinetics for Fiduciary Breaches

1d agoPRnewswire

Vertex's $10B Crinetics Acquisition Sparks Biotech M&A Speculation

29m agostocktwits

Crinetics Hits Record High After Vertex's $10 Billion Acquisition

2h agostocktwits

Vertex Acquires Crinetics for $10 Billion

2h agoFool

Vertex Acquires Crinetics for $85 Per Share in Cash

2h agoNASDAQ.COM

Crinetics Hits Record High After Vertex Acquisition Deal

2h agoYahoo Finance

US Stocks Close Lower as Chipmakers Weigh on Market

7h agoNASDAQ.COM

ServiceNow and Maplebear Options Trading Activity Surges

10h agoNASDAQ.COM

CRNX Events

07/07 16:30
TD Cowen Downgrades Crinetics to Hold
TD Cowen analyst Tyler Van Buren downgraded Crinetics (CRNX) to Hold from Buy with no price target after Vertex Pharmaceuticals (VRTX) announced an agreement to acquire the the company for $85 per share in cash. Given the "impressive" 102% premium, the firm expects the deal to close Q3 and adds that Vertex "will receive one of the most robust endocrine pipelines."
07/07 16:30
Nasdaq Retreats Amid Chip Sector Declines
Stock indexes retreated amid losses for the heavyweight chip sector, making the Nasdaq the laggard, while the Dow pulled back from a record high reached in morning trading. Memory producers sank even though Samsung posted a 19-fold surge in profit last quarter. The surge was in line with the sector's rally this year, but markets appear to be growing increasingly skeptical on whether AI hyperscalers can justify elevated levels of capital expenditure on infrastructure. Yields edged higher after attacks on an LNG tanker in the Middle East tempered hopes of lower energy inflation.Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. v1. STOCK NEWS:Walmartsaid it would cut prices on many summer staplesfrom President Trump saying the retail giant was doing so at his requestChina's DeepSeek is developing its own AI chip in a push to reduce reliance on Nvidiaand Huawei chips,Vertex Pharmaceuticalsto acquire Crinetics Pharmaceuticalsfor $85 per share in cash, for a total equity value of approximately $10BSamsung Electronicsreported, but the AI-fueled earnings still failed to meet high investor expectationsMetadebuted its, saying it will help power image generation in Meta Advantage+ creative "in the coming weeks"2. WALL STREET CALLS:Wall Streetof SpaceX, including Raymond James starting the stock with a Strong Buy rating and $800 price targetScotiabankCloudflareto OutperformBofAAdobeat Underperform with a $190 price target, down from the Buy rating the firm previously heldDeutsche BankFirst Solarto BuyMelius ResearchAmerican Airlinesto Hold3. AROUND THE WEB:Big banks have held talks in recent months to buy a card network owned by Fiserv, Reuters and WSJ reportMicrosoftwill replace OpenAI and Anthropic with its own AI in some apps, Bloomberg saysMetasaid four states are seeking $1.4T in penalties over accusations it designed its social media platforms to addict young users and misled the public on their safety, Reuters reportsAmazonis seeking to raise at least $25B through a U.S. dollar bond sale to fund investments in artificial intelligence infrastructure, Bloomberg reportsPresident Trump is expected to support a potential sale of Lockheed Martin'sF-35 Lightning II jets to Turkey during a visit to Ankara, Reuters says4. MOVERS:Digital Oceangained afterit expects Q2 RPO to exceed $800MRedwood Trustwas higher after highlightingFigmaincreased after BofAcoverage with a Buy ratingRivianwas lower after75M shares of stockUnited States Antimonyfell after announcing the5. EARNINGS/GUIDANCE:Interactive Strengthraised itsCosmos HealthreportedShellissued anAbbVieprovided itsand cut its guidance for FY26Sealsqreportedand backed its guidance for FY26INDEXES:The Dow fell 130.76, or 0.25%, to 52,925.15, the Nasdaq lost 302.47, or 1.16%, to 25,818.69, and the S&P 500 declined 33.58, or 0.45%, to 7,503.85.
07/07 13:00
Citizens Analyst Downgrades Crinetics to Market Perform After $85 Acquisition by Vertex Pharmaceuticals
Citizens analyst Jonathan Wolleben downgraded Crinetics (CRNX) to Market Perform from Outperform after Vertex Pharmaceuticals (VRTX) agreed to acquire the company for $85 per share in cash.

CRNX Monitor News

Crinetics Pharmaceuticals Surges After $10 Billion Vertex Acquisition

Jul 07 2026

Crinetics Pharmaceuticals Reports Strong Q1 2026 Earnings and Regulatory Progress

May 08 2026

Crinetics Pharmaceuticals Raises $350M Through Share Offering

Jan 07 2026

Crinetics Pharmaceuticals Reports Positive Phase 2 Results for Atumelnant

Jan 05 2026

CRNX Earnings Analysis

Crinetics Pharmaceuticals Inc Reports ThirdQuarter Financial Results
1 years ago

People Also Watch